[A case of systemic lupus erythematosus with pulmonary hypertension].
A 15 year-old girl was admitted to the hospital because of fever, polyarthlargia, dry cough, dyspnea, butterfly rash and multiple oral aphthas. The diagnosis of systemic lupus erythematosus (SLE) was made based on renal disorders, pancytopenia, positive antinuclear antibody and positive for antibodies to double-stranded DNA. On admission, she developed progressive dyspnea with highly active SLE. The patient was complicated with both pulmonary hypertension (PH) and interstitial pneumonitis (IP), judging from increased pulmonary sound by an auscultation, interstitial shadows especially at bilateral lower lung and enlarged shadow of right atrium in a chest rentgenogram, ground glass pattern of bilateral middle to lower lung in a chest computed tomographic scan, increased pulmonary artery pressure, 53 mmHg, by an ultrasound cardiograph (UCG). Combination of methylprednisolone pulse therapy, cyclosporin A and plasma exchanges was effectively administered, which resulted in improvement of disease activity of SLE, IP and PH. However, two months later, although disease activity of SLE was completely reduced, recurrence of PH by UCG and multiple pulmonary embolism (PE) which was observed by a chest rentgenogram and a pulmonary blood flow scintigraphy was further complicated. Administration of cyclophosphamide pulse therapy and warfarin therapy improved both PE and PH. The patient had PH at the different clinical course of SLE; 1) PH maybe induced by severe IP at the active phase of SLE and 2) PH brought about from multiple PE at the inactive phase of SLE. Thus, the case is thought to be suggestive of elucidating the pathogenesis of PH of several systemic autoimmune diseases including SLE.
Nakano
K
K
First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu-city.
Tanaka
Y
Y
Aso
M
M
Saito
K
K
Fujii
K
K
Takazawa
A
A
Ota
T
T
D000293:Adolescent; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology*; D017563:Lung Diseases, Interstitial / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D010951:Plasma Exchange; D011655:Pulmonary Embolism / Q000209:etiology / Q000628:therapy; D020551:Pulse Therapy, Drug; D012008:Recurrence; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
D014859:Warfarin; D003520:Cyclophosphamide